周奇
职称:主任医师
科室:肝外科
简介:   主治原发性肝癌、胆囊癌、胆管癌、胰腺癌、肝血管瘤、门脉高压、上消化道出血、肝内外胆管结石等良恶性疾病。擅长胆囊癌根治术;肝门部胆管癌根治术;复杂胆道结石手术;胰头、体尾癌根治术;微创肝切除、胆囊切除,肝癌射频消融术等。对原发性肝癌侵袭转移治疗有丰富经验。
出诊时间
专家门诊
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出诊时间以实际为准

医疗特长:

    主治原发性肝癌、胆囊癌、胆管癌、胰腺癌、肝血管瘤、门脉高压、上消化道出血、肝内外胆管结石等良恶性疾病。擅长胆囊癌根治术;肝门部胆管癌根治术;复杂胆道结石手术;胰头、体尾癌根治术;微创肝切除、胆囊切除,肝癌射频消融术等。对原发性肝癌侵袭转移治疗有丰富经验。

 

研究方向:

肝胆胰脾临床和基础研究。

 

主要教育和工作经历:

学习经历:

2001年9月-2004年6月: 中山大学外科学专业就读,获得博士学位。

工作经历:

2004年7月-至今:中山大学附属第一医院肝胆外科主治医师、副主任医师、主任医师

 

社会兼职:

中国医药教育协会医疗装备工作委员会副主任委员;广东省健康管理学会肝胆胰微创专委会主任委员;广东省医学会肝胆胰外科学分会术中辅助诊断学组组长;广东省医师协会肝癌学组副组长。

 

 

论著:

1、Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis andpromotes tumor progression by regulating P21/CDK2 in hepatocellular Carcinoma《AGING》2020

2、Bioinformatics analysis on multiple Gene Expression Omnibus datasets ofthe hepatitis B virus infection and its response to the interferon-alphatherapy《BMC Infectious Diseases》2020

3、Uridine-cytidine kinase 2 upregulation predicts poor prognosis ofhepatocellular carcinoma and is associated with cancer aggressiveness.《Molecular Carcinogenesis》  2019

4、Apatinib potentiates irradiation effect via suppressing PI3K/AKTsignaling pathway in hepatocellular carcinoma.《Journalof Experimental & Clinical Cancer Research》2019

5、Comprehensive and combined omics analysis revealsfactors of ischemia-reperfusion injury in liver transplantation. 《Epigenomics》  2019

6、Targeting TF-AKT/EGFR Pathway Suppressed theGrowth Of Hepatocellular Carcinoma. 《Frontiers in Oncology》  2019

7、A comprehensive bioinformatics analysis onmultiple Gene Expression Omnibus datasets of nonalcoholic fatty liver diseaseand nonalcoholic steatohepatitis. 《Sci Rep》  2018

8、Overexpression of signal sequence receptor γ(SSR3) predicts poor survival in patients with hepatocellular carcinoma.《Hum Pathol》  2018

9、Formylpeptide receptor 1 mediates thetumorigenicity of human hepatocellular carcinoma cells.《OncoImmunology》 2016

10、High expression of hexokinase domain containing 1is associated with poor prognosis and aggressive phenotype in hepatocarcinoma.《Biochemical and Biophysical ResearchCommunications》  2016

11、Adult hepatic cavernous hemangioma with highlyelevated α?fetoprotein: A case report and review of the literature.《Oncol Lett》 2015

12、Arterial infusion of 5-fluorouracil combined withsubcutaneous injection of pegylated interferon alpha-2b in treatingunresectable hepatocellular carcinoma with portal vein tumor thrombus.《Med Oncol》 2015

13、Inhibition of Wnt signaling induces cellapoptosis and suppresses cell proliferation in cholangiocarcinoma cells.《Oncol Rep》 2013

14、The roles of Notch1 expression in the migrationof intrahepatic cholangiocarcinoma.《BMC Cancer》 2013

15、Development of IGF Signaling Antibody Arrays forthe Identification of Hepatocellular Carcinoma Biomarkers.《 PLos One》 2012

16、Identification of Max binding protein as a novelbinding protein of Nck1 and characterization of its role in inhibiting humanliver cancer SK-HEP-1 cells. 《Chinese Medical Journal》 2012

17、Experimental study of single-pin punctureasymmetrical hydroablation using a conformational radiofrequency ablationelectrode in ex vivo ox liver.《The British Journal of Radiology》 2012

18、Killing effects of different physical factors onextracorporeal HepG2 cells of human Hepatoma cell line.《Asian Pacific Journal of Cancer Prevention》 2012

19、Microwave Ablation Treatment of Liver Cancer witha 2,450-MHz Cooled-shaft Antenna: Pilot Study on Safety and Efficacy.《Asian Pacific Journal of Cancer Prevention》 2012

20、MNT inhibits the migration of humanhepatocellular carcinoma SMMC7721 cells.《Biochemical and Biophysical ResearchCommunications》 2012

21、Prognostic Analysis for Treatment Modalities inHepatocellular Carcinomas with Portal Vein Tumor Thrombi.《 Asian Pacific Journal of Cancer Prevention》2011

 

专著:

《肝胆胰脾外科并发症学》

 

其他主要工作成绩(比如获奖情况):

广东省高等学校“千百十工程”第五批人才培养对象,广东省健康管理协会先进个人,曾在美国ST-Vicent Hospital 肝胆胰中心进行临床培训。主持省市基金12项。在国内外核心期刊发表论文60余篇,以第一作者或通讯作者发表SCI论文30余篇。广东省医学科技成果二等奖。